Regeneron revenue advances to $4.29B as growth accelerates

• Regeneron reported second-quarter 2026 revenue of $4.29 billion, up 17% year over year.
• Non-GAAP diluted EPS increased 11% to $14.29, while Dupixent and Libtayo sales grew.
• The company updated 2026 guidance after repaying its Sanofi Development Balance and adjusting investment plans.

Regeneron Pharmaceuticals (NASDAQ:REGN) reported second-quarter 2026 total revenue of $4.29 billion, up 17% year over year, supported by higher collaboration revenue and product sales growth.

GAAP net income was $1.30 billion, or $12.23 per diluted share, while non-GAAP net income increased 8% to $1.54 billion and non-GAAP diluted EPS rose 11% to $14.29.

Dupixent global net sales recorded by Sanofi increased 38% to $6 billion, EYLEA HD U.S. net sales increased 52% to $596 million and Libtayo global net sales rose 30% to $489 million, while total U.S. EYLEA HD and EYLEA net product sales declined 12% to $1.01 billion.

Regeneron updated its 2026 financial outlook, including higher expected gross margins and lower capital expenditure guidance.

Sanofi collaboration revenue increased 51% to $2.17 billion due to higher antibody profits, while the Sanofi Development Balance was fully repaid, removing the impact of that balance from collaboration revenue from Q3 2026 onward.

Meanwhile, Regeneron advanced multiple pipeline programmes, including regulatory progress for Dupixent, EYLEA HD and cemdisiran, while repurchasing $1.2 billion of stock in the second quarter and declaring a $0.94 per share dividend.